Implementation of agents targeting membrane transporters, especially SGLT2 inhibitors, resulted in changes in clinical guidelines for the treatment of common diseases, such as diabetes mellitus and heart failure. The gene discussed is SLC5A2; the disease is diabetes mellitus.